Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease

Neurology

Volumn 80, Issue 2, 2013, Pages 169-175

  Besong Agbo, Daniela ^a   Wolf, Elias ^a   Jessen, Frank ^b,c   Oechsner, Matthias ^d   Hametner, Eva ^e   Poewe, Werner ^e   Reindl, Markus ^e   Oertel, Wolfgang H ^a   Noelker, Carmen ^a   Bacher, Michael ^a   Dodel, Richard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d Parkinson Klinik Bad Nauheim   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN AUTOANITBODY; AUTOANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84873641251     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827b90d1     Document Type: Article

References (32)

1. El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003;17:1945-1947.
2. Fjorback AW, Varming K, Jensen PH. Determination of alpha-synuclein concentration in human plasma using ELISA. Scand J Clin Lab Invest 2007;67:431-435. (Pubitemid 46897610)
3. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213:315-325.
4. Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 2009;450:332-335.
5. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162-166. (Pubitemid 44331776)
6. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synu-clein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-726.
7. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Syn-uclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-240.
8. Shi M, Zabetian CP, Hancock AM, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 2010;480:78-82.
9. Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodege-ner Dis 2008;5:55-59.
10. Papachroni KK, Ninkina N, Papapanagiotou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007;101:749-756. (Pubitemid 46633311)
11. Agbo DB, Neff F, Seitz F, et al. Immunization as treatment for Parkinson's disease. J Neural Transm Suppl 2009:311-315.
12. Gibb WR. Accuracy in the clinical diagnosis of parkinso-nian syndromes. Postgrad Med J 1988;64:345-351.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
15. Tinsley RB, Kotschet K, Modesto D, et al. Sensitive and specific detection of alpha-synuclein in human plasma. J Neurosci Res 2010;88:2693-2700.
16. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-35.
17. Chen S, Le WD, Xie WJ, et al. Experimental destruction of substantia nigra initiated by Parkinson disease immu-noglobulins. Arch Neurol 1998;55:1075-1080. (Pubitemid 28367232)
18. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005;128:2665-2674. (Pubitemid 41552950)
19. Brody DL, Holtzman DM. Active and passive immuno-therapy for neurodegenerative disorders. Annu Rev Neuro-sci 2008;31:175-193.
20. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005;46:857-868. (Pubitemid 40805347)
21. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA. alpha-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 2011;6:e18513.
22. Notkins AL. Polyreactivity of antibody molecules. Trends Immunol 2004;25:174-179. (Pubitemid 38368164)
23. Szabo P, Mujalli DM, Rotondi ML, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 2010;227:167-174.
24. Klaver AC, Patrias LM, Coffey MP, Finke JM, Loeffler DA. Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods 2010;187:263-269.
25. Pellegrino NM, Caccavo D. Variability in anticardiolipin antibody detection: role of nonspecific IgG binding and different microtiter plates. Clin Appl Thromb Hemost 2007;13:404-409. (Pubitemid 350114517)
26. Dodel R, Neff F, Noelker C, et al. Intravenous immuno-globulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010;70:513-528.
27. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987;69:557-565. (Pubitemid 17125559)
28. Candore G, Di Lorenzo G, Mansueto P, et al. Prevalence of organ-specific and non organ-specific autoantibodies in healthy centenarians. Mech Ageing Dev 1997;94:183-190. (Pubitemid 27216106)
29. Brettschneider S, Morgenthaler NG, Teipel SJ, et al. Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol Psychiatry 2005;57:813-816. (Pubitemid 40487927)
30. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002;37:943-948. (Pubitemid 34665486)
31. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:127-132. (Pubitemid 44259784)
32. Henchcliffe C, Dodel R, Beal MF. Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Prog Neu-robiol 2011;95:601-613.